Ophthotech Corp (OPHT) Reports Acquisition of Inception 4 Inc. to Expand Innovative Retinal Disease Pipeline

Ophthotech Corp (OPHT) Tops Q3 EPS by 2c

Ophthotech Corp (NASDAQ: OPHT) reported Q3 EPS of ($0.41), $0.02 better than the analyst estimate of ($0.43).

During 2018 Ophthotech made significant progress in bringing together a diversified pipeline of therapeutic and gene therapy programs for the treatment of retinal diseases, stated Glenn P. Sblendorio, Chief Executive Officer... More